Abstract
Purpose
DCBLD2 expression dysregulation has been reported in several types of human cancer. As yet, however, the role of DCBLD2 in colorectal cancer (CRC) is not known.
Methods
CRC tissues were obtained from patients undergoing surgery from February 2009 to May 2014 (n = 90). Tissue microarray construction and immunohistochemistry were carried out to determine DCBLD2 expression. In vivo studies were performed in 4-week-old BALB/c nude mice. In vitro studies were conducted using CRC-derived HT29 and HCT116 cell lines.
Results
DCBLD2 expression was found to be significantly increased in CRC tissues compared to adjacent normal tissues (p < 0.001). In addition, we found that DCBLD2 expression was positively correlated with the stage of the disease, the degree of differentiation and vascular invasion. High DCBLD2 expression was significantly associated with a poor overall survival. In vitro, DCBLD2 expression downregulation significantly reduced CRC cell proliferation and invasion. In a mouse xenograft model, DCBLD2 expression downregulation reduced lung metastasis and increased overall survival. Gene set enrichment analysis (GSEA) revealed that DCBLD2 overexpression induces epithelial–mesenchymal transition (EMT) and activates the JAK/STAT3 pathway.
Conclusions
We found that high DCBLD2 expression correlated with a poor clinical outcome, as well as tumorigenesis, invasion and metastasis of CRC cells. DCBLD2 may serve as a prognostic biomarker and a novel therapeutic target for CRC.
Similar content being viewed by others
References
R.C. Bates, A.M. Mercurio, The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol. Ther. 4, 365–370 (2005). https://doi.org/10.4161/cbt.4.4.1655
S.D. Markowitz, D.M. Dawson, J. Willis, J.K. Willson, Focus on colon cancer. Cancer Cell 1, 233–236 (2002). https://doi.org/10.1016/S1535-6108(02)00053-3
L. Wei, X. Wang, L. Lv, Y. Zheng, N. Zhang, M. Yang, The emerging role of noncoding RNAs in colorectal cancer chemoresistance. Cell. Oncol. 42, 757–768 (2019). https://doi.org/10.1007/s13402-019-00466-8
D. Liu, Concomitant dysregulation of the estrogen receptor and BRAF/MEK signaling pathways is common in colorectal cancer and predicts a worse prognosis. Cell. Oncol. 42, 197–209 (2019). https://doi.org/10.1007/s13402-018-00420-0
M.S. Pepe, R. Etzioni, Z. Feng, J.D. Potter, M.L. Thompson, M. Thornquist, M. Winget, Y. Yasui, Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 93, 1054–1061 (2001). https://doi.org/10.1093/jnci/93.14.1054
K. Kobuke, Y. Furukawa, M. Sugai, K. Tanigaki, N. Ohashi, A. Matsumori, S. Sasayama, T. Honjo, K. Tashiro, ESDN, a novel neuropilin-like membrane protein cloned from vascular cells with the longest secretory signal sequence among eukaryotes, is up-regulated after vascular injury. J. Biol. Chem. 276, 34105–34114 (2001). https://doi.org/10.1074/jbc.M105293200
K. Koshikawa, H. Osada, K. Kozaki, H. Konishi, A. Masuda, Y. Tatematsu, T. Mitsudomi, A. Nakao, T. Takahashi, Significant up-regulation of a novel gene, CLCP1, in a highly metastatic lung cancer subline as well as in lung cancers in vivo. Oncogene 21, 2822–2828 (2002). https://doi.org/10.1038/sj.onc.1205405
M. Goujon, H. McWilliam, W. Li, F. Valentin, S. Squizzato, J. Paern, R. Lopez, A new bioinformatics analysis tools framework at EMBL-EBI. Nucl Acids Res. 38, W695–W699 (2010). https://doi.org/10.1093/nar/gkq313
H. Nielsen, Predicting secretory proteins with SignalP. Methods Mol. Biol. 1611, 59–73 (2017). https://doi.org/10.1007/978-1-4939-7015-5_6
T.M. Aten, M.M. Redmond, S.O. Weaver, C.C. Love, R.M. Joy, A.S. Lapp, O.D. Rivera, K.L. Hinkle, B.A. Ballif, Tyrosine phosphorylation of the orphan receptor ESDN/DCBLD2 serves as a scaffold for the signaling adaptor CrkL. FEBS Lett. 587, 2313–2318 (2013). https://doi.org/10.1016/j.febslet.2013.05.064
A.M. Schmoker, J.L. Weinert, K.J. Kellett, H.E. Johnson, R.M. Joy, M.E. Weir, A.M. Ebert, B.A. Ballif, Dynamic multi-site phosphorylation by Fyn and Abl drives the interaction between CRKL and the novel scaffolding receptors DCBLD1 and DCBLD2. Biochem J. 474, 3963–3984 (2017). https://doi.org/10.1042/bcj20170615
L. Nie, X. Guo, L. Esmailzadeh, J. Zhang, A. Asadi, M. Collinge, X. Li, J.D. Kim, M. Woolls, S.W. Jin, A. Dubrac, A. Eichmann, M. Simons, J.R. Bender, M.M. Sadeghi, Transmembrane protein ESDN promotes endothelial VEGF signaling and regulates angiogenesis. J. Clin. Invest. 123, 5082–5097 (2013). https://doi.org/10.1172/jci67752
X. Li, J.J. Jung, L. Nie, M. Razavian, J. Zhang, V. Samuel, M.M. Sadeghi, The neuropilin-like protein ESDN regulates insulin signaling and sensitivity. Am. J. Phys. Heart Circ. Phys. 310, H1184–H1193 (2016). https://doi.org/10.1152/ajpheart.00782.2015
M.N. O'Connor, A. Salles II, A. Cvejic, N.A. Watkins, A. Walker, S.F. Garner, C.I. Jones, I.C. Macaulay, M. Steward, J.J. Zwaginga, S.L. Bray, F. Dudbridge, B. de Bono, A.H. Goodall, H. Deckmyn, D.L. Stemple, W.H. Ouwehand, Functional genomics in zebrafish permits rapid characterization of novel platelet membrane proteins. Blood 113, 4754–4762 (2009). https://doi.org/10.1182/blood-2008-06-162693
H. Feng, G.Y. Lopez, C.K. Kim, A. Alvarez, C.G. Duncan, R. Nishikawa, M. Nagane, A.J. Su, P.E. Auron, M.L. Hedberg, L. Wang, J.J. Raizer, J.A. Kessler, A.T. Parsa, W.Q. Gao, S.H. Kim, M. Minata, I. Nakano, J.R. Grandis, R.E. McLendon, D.D. Bigner, H.K. Lin, F.B. Furnari, W.K. Cavenee, B. Hu, H. Yan, S.Y. Cheng, EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J. Clin. Invest. 124, 3741–3756 (2014). https://doi.org/10.1172/jci73093
E. Hofsli, T.E. Wheeler, M. Langaas, A. Laegreid, L. Thommesen, Identification of novel neuroendocrine-specific tumour genes. Br. J. Cancer 99, 1330–1339 (2008). https://doi.org/10.1038/sj.bjc.6604565
H. Xiong, J. Hong, W. Du, Y.W. Lin, L.L. Ren, Y.C. Wang, W.Y. Su, J.L. Wang, Y. Cui, Z.H. Wang, J.Y. Fang, Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J. Biol. Chem. 287, 5819–5832 (2012). https://doi.org/10.1074/jbc.M111.295964
T. Kato, S. Hayama, T. Yamabuki, N. Ishikawa, M. Miyamoto, T. Ito, E. Tsuchiya, S. Kondo, Y. Nakamura, Y. Daigo, Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1 is associated with tumor progression in patients with lung cancer. Clin Cancer Res 13, 434–442 (2007). https://doi.org/10.1158/1078-0432.CCR-06-1297
Y.R. Weng, Y.N. Yu, L.L. Ren, Y. Cui, Y.Y. Lu, H.Y. Chen, X. Ma, W.X. Qin, W. Cao, J. Hong, J.Y. Fang, Role of C9orf140 in the promotion of colorectal cancer progression and mechanisms of its upregulation via activation of STAT5, beta-catenin and EZH2. Carcinogenesis 35, 1389–1398 (2014). https://doi.org/10.1093/carcin/bgu057
M. Kim, K.T. Lee, H.R. Jang, J.H. Kim, S.M. Noh, K.S. Song, J.S. Cho, H.Y. Jeong, S.Y. Kim, H.S. Yoo, Y.S. Kim, Epigenetic down-regulation and suppressive role of DCBLD2 in gastric cancer cell proliferation and invasion. Mol. Cancer Res. 6, 222–230 (2008). https://doi.org/10.1158/1541-7786.MCR-07-0142
I. Fukumoto, T. Kinoshita, T. Hanazawa, N. Kikkawa, T. Chiyomaru, H. Enokida, N. Yamamoto, Y. Goto, R. Nishikawa, M. Nakagawa, Y. Okamoto, N. Seki, Identification of tumour suppressive microRNA-451a in hypopharyngeal squamous cell carcinoma based on microRNA expression signature. Br. J. Cancer 111, 386–394 (2014). https://doi.org/10.1038/bjc.2014.293
S.M. Pagnotta, C. Laudanna, M. Pancione, L. Sabatino, C. Votino, A. Remo, L. Cerulo, P. Zoppoli, E. Manfrin, V. Colantuoni, M. Ceccarelli, Ensemble of gene signatures identifies novel biomarkers in colorectal cancer activated through PPARgamma and TNFalpha signaling. PLoS One 8, e72638 (2013). https://doi.org/10.1371/journal.pone.0072638
Y. Chen, T.Y. Low, L.Y. Choong, R.S. Ray, Y.L. Tan, W. Toy, Q. Lin, B.K. Ang, C.H. Wong, S. Lim, B. Li, C.L. Hew, N.S. Sze, B.J. Druker, Y.P. Lim, Phosphoproteomics identified Endofin, DCBLD2, and KIAA0582 as novel tyrosine phosphorylation targets of EGF signaling and Iressa in human cancer cells. Proteomics 7, 2384–2397 (2007). https://doi.org/10.1002/pmic.200600968
A. Loboda, M.V. Nebozhyn, J.W. Watters, C.A. Buser, P.M. Shaw, P.S. Huang, L. Van't Veer, R.A. Tollenaar, D.B. Jackson, D. Agrawal, H. Dai, T.J. Yeatman, EMT is the dominant program in human colon cancer. BMC Med. Genet. 4, 9 (2011). https://doi.org/10.1186/1755-8794-4-9
R. Kalluri, R.A. Weinberg, The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420–1428 (2009). https://doi.org/10.1172/JCI39104
J.H. Tsai, J. Yang, Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 27, 2192–2206 (2013). https://doi.org/10.1101/gad.225334.113
S. Lamouille, J. Xu, R. Derynck, Molecular mechanisms of epithelial-mesenchymal transition. Nature Rev. Mol. Cell Biol. 15, 178–196 (2014). https://doi.org/10.1038/nrm3758
A. Ganguly, H. Yang, R. Sharma, K.D. Patel, F. Cabral, The role of microtubules and their dynamics in cell migration. J. Biol. Chem. 287, 43359–43369 (2012). https://doi.org/10.1074/jbc.M112.423905
D.C. Ng, B.H. Lin, C.P. Lim, G. Huang, T. Zhang, V. Poli, X. Cao, Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J. Cell. Biol. 172, 245–257 (2006). https://doi.org/10.1083/jcb.200503021
M. Colomiere, A.C. Ward, C. Riley, M.K. Trenerry, D. Cameron-Smith, J. Findlay, L. Ackland, N. Ahmed, Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Brit. J. Cancer 100, 134–144 (2009). https://doi.org/10.1038/sj.bjc.6604794
M. Rokavec, M.G. Oner, H. Li, R. Jackstadt, L. Jiang, D. Lodygin, M. Kaller, D. Horst, P.K. Ziegler, S. Schwitalla, J. Slotta-Huspenina, F.G. Bader, F.R. Greten, H. Hermeking, IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J. Clin. Invest. 124, 1853–1867 (2014). https://doi.org/10.1172/JCI73531
Acknowledgments
This work was supported by the Natural Science Foundation of Guangdong Province, China (No. 2018A030313676), Guangdong Planned Project of Science and Technology (No.2017B020226001), Guangzhou Planned Project of Science and Technology (No. 201707010275), and the Fundamental Research Funds for the Central Universities (No. 2017ZD104).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Ethical approval
The Ethics Committee of Guangzhou First Hospital approved the study protocol. The Institutional Animal Care and Use Committee approved the experimental procedures. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Written informed consent was obtained from all individual participants included in this study.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOC 10260 kb)
Rights and permissions
About this article
Cite this article
He, J., Huang, H., Du, Y. et al. Association of DCBLD2 upregulation with tumor progression and poor survival in colorectal cancer. Cell Oncol. 43, 409–420 (2020). https://doi.org/10.1007/s13402-020-00495-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13402-020-00495-8